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Abstract
Background: Coccidioidomycosis (CM) infections among transplant 
recipients result in significant morbidity and mortality. The goal of 
our study was to establish the efficacy of low dose (LD) versus stand-
ard dose (LD, 50 mg daily) fluconazole in preventing CM infection.
Methods: This was a retrospective study utilizing electronic medical 
records of liver transplant recipients at the University of Arizona. The 
primary end point was post-transplant CM status, such as infection, 
complications and survival.
Results: We detected a statistically significant correlation between 
positive pre-transplant status and positive post-transplant status (haz-
ards ratio: 8.25 (95% confidence interval: 1.028 - 66.192)). There was 
a trend towards improved survival in patients who had a positive post-
transplant CM status in the SD group versus LD group (90.9% versus 
81.3%), although not statistically significant.
Conclusion: The risk of CM infection among transplant recipients 
in the absence of prophylaxis is associated with high morbidity and 
mortality. We currently use SD fluconazole as universal prophylaxis 
in all transplant recipients despite not establishing statistical signifi-
cance between LD and SD. We believe that the survival trend detected 
may have not reached statistical significance due to low power im-
pact. Since the standardization of SD prophylaxis at our institution, 
we have not diagnosed further new post-transplant CM infections.
Keywords: Coccidioidomycosis; Fungal infection; Prophylaxis; 
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Introduction
The dimorphic fungi, Coccidioides immitis/posadasii, are en-
demic to Southwestern United States, Northern Mexico, Cen-
tral America and South America. Coccidioidomycosis (CM), 
also known as San Joaquin Valley fever, is associated with 
infections among immunocompromised patients including 
transplant recipients and can result in significant morbidity and 
mortality in this population. In 2015, there were 7,622 cases of 
CM reported in Arizona [1]. The risk of infection among solid-
organ transplant (SOT) recipients in endemic regions in the 
absence of prophylaxis during the early transplantation years 
has been reported to be 7-9% with a high rate of dissemination 
of up to 75% and mortality of 63% [2]. In most cases, infec-
tion is thought to be a result of reactivation of prior exposure 
[2] and the majority of these infections occur within the first 
year after transplantation. Although there are no established 
guidelines, the Infectious Diseases Society of America (IDSA) 
does recommend prophylaxis for special at-risk populations 
[3] and most transplant centers have protocols for prophylaxis 
for transplant recipients. Transplant recipients at the Univer-
sity of Arizona previously received fluconazole 50 mg daily 
as prophylaxis for an indefinite period of time. The efficacy of 
this practice had not been established by major studies. Trans-
plant centers in the endemic area use different approaches for 
the prevention of CM in their recipients. Blair et al recently 
reported data that universal prophylaxis with fluconazole 200 
mg daily for 12 months after liver transplantation was effec-
tive for those residing in endemic regions [4]. The aims of our 
study were to 1) establish the risk of new CM infection or reac-
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tivation in liver transplant recipients living in Arizona, receiv-
ing prophylaxis with fluconazole dose of less than 200 mg/
day versus 200 mg/day, 2) assess the risk of infection among 
groups who received prophylaxis for less than 6 months, be-
tween 6 and 12 months and more than 12 months and 3) es-




This was a retrospective study where we reviewed the elec-
tronic medical records (EMR) of liver transplant recipients at 
the University of Arizona. Inclusion criteria considered 1) all 
adult and pediatric patients who underwent liver transplanta-
tion from January 1, 1998 through May 31, 2012 and 2) all 
patients who had CM serology testing performed during this 
period. Exclusion criteria considered 1) patients who received 
treatment dose antifungal therapy at the time of their trans-
plantation and/or 2) patients who had incomplete data regard-
ing prophylaxis status in the charts. Study participants were 
categorized into two groups according to the prophylaxis dose: 
1) low dose (LD) prophylaxis group: < 200 mg per day of flu-
conazole (< 6 mg/kg/day for pediatric patients) and 2) standard 
dose (SD) prophylaxis group: 200 mg per day of fluconazole 
(6 mg/kg/day for pediatric patients). The primary end point of 
the study was the post-transplant CM status, such as infection, 
complications and survival. The study was conducted in com-
pliance with the ethical standards of the responsible institution 
on human subjects as well as with the Helsinki Declaration. 
The University of Arizona Institutional Review Board (IRB) 
approved the study.
Data collection
Laboratory results data as well as progress notes, admission 
history, surgical reports, discharge summaries and scanned 
medical documents in our inpatient and outpatient EMR were 
searched. Data collected included demographic information, 
etiology of liver failure, other comorbid conditions, immuno-
suppressive regimen, rejection episodes and treatment, and do-
nor details when available.
Data pertaining to study key elements included pre-trans-
plantation CM serology, reported or confirmed history of prior 
CM infection and antifungal therapy information. We also 
obtained information that included: post-transplantation se-
rology, microbiology and cytology or histopathology reports 
indicating evidence of CM infection. When present, the site 
of infection (pulmonary, extra-pulmonary, or both) as well as 
initiation of antifungal therapy was recorded.
To complement and verify information about CM disease 
status, we asked our State Health Department office to cross 
reference our list of cases with CM cases reported to the state 
since 1997, as some patients could have been diagnosed, tested 
or treated in other institutions before or after transplant. With 
all the information required completed, we reviewed our pa-
tient list to determine if positive testing results were reported 
before or after transplantation.
Living status was collected and confirmed though EMR. 
When the information was not available, we completed the sta-
tus checking our records and the Social Security office infor-
mation at the end of our review period (May 31, 2014). When 
available, cause of death was recorded from EMR.
CM status
Most liver transplant candidates had CM serology testing per-
formed as part of their pre-transplant evaluation. At the time, 
there were no set guidelines for post-transplant serology test-
ing and most were performed on a case-by-case basis. Sero-
logic testing, cultures, or histopathology specimens had been 
obtained when a CM was clinically suspected. Close to half 
of the patients included in this study had serologic testing per-
formed at least once in the post-transplant period (38 patients 
out of 78) (Fig. 1).
Definitions
Positive pre-transplant CM status included reactive or indeter-
minate serology results by immunoglobulin G (IgG) or immuno-
globulin M (IgM) antibodies via immunodiffusion, complement 
fixation, and/or enzyme immunoassay (EIA) methods. A self-
reported or physician reported past history of CM were also con-
sidered as a positive pre-transplant CM status. Physician docu-
mented infections diagnosed by microbiology (culture and DNA 
probe) or histopathology pre-transplant were also included.
Positive post-transplant CM status included reactive or 
indeterminate serology by IgG or IgM antibodies via immuno-
diffusion, complement fixation, and/or or EIA methods, micro-
biology (culture and DNA probe) and/or histopathology.
CM serology
The CM serology testing method utilized at our laboratory 
changed in the middle of 2012. Before 2012, our medical cent-
er used the Meridian Bioscience, Inc® test kits, an immunodif-
fusion method. In 2012, the testing method was changed to 
EIA by Immy® which was the testing method employed at the 
time this study was completed. The microbiology and histo-
pathology data that were recorded during data collection were 
performed at our institution’s laboratories.
CM prophylaxis
Patients were categorized into two groups according to the 
dose of antifungal agents they received for prophylaxis. The 
patients were divided into LD prophylaxis group or SD proph-
ylaxis group. The decision to prescribe LD or SD fluconazole 
was up to prescribing physician. The patients were then further 
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categorized into three groups based on the duration of prophy-
laxis received post-transplantation (6 months, 12 months, or 
greater than 12 months).
A positive pre- or post-transplant CM status incidence rate 
among liver transplant recipients was calculated from the data 
collected, and the results were compared between the above-
defined groups.
Immunosuppression
Use of immunosuppression (including induction therapy) as 
well as number and choice of maintenance agents was com-
pared among patient groups. Episodes of rejection along with 
receipt of steroid boluses, thymoglobulin, or monoclonal anti-
bodies were also taken into consideration when analyzing pa-
tient immunosuppression status.
Statistical analysis
Data were analyzed with SPSS version 22 IBM®. We used 
simple descriptive statistics for analysis of the data obtained 
in the study. Fisher’s exact test with two-sided significance 
was used to assess differences among proportions of various 
attributes of patients classified according to dosage (LD or 
SD). Continuous variables were analyzed and compared be-
tween the LD and SD groups and between the three duration 
groups with independent sample t-test. Kaplan-Meier survival 
analysis with log-rank test was used to assess patient survival 
between LD and SD groups.
Results
A total of 119 patients underwent liver transplantation surgery 
between January 1, 1998 and May 31, 2012. All 119 charts 
were reviewed, 40 were excluded due to insufficient documen-
tation and one was excluded due to having active CM pneu-
monia diagnosed immediately after transplantation and was 
placed on antifungal therapy. Out of the 78 patients remaining, 
38 were suspected of having CM post-transplant and therefore 
had post-transplant workup performed. All 78 patients were 
included in data analysis.
Patient characteristics
Patient baseline characteristics are summarized in Table 1. 
There were 11 patients in the SD prophylaxis group, seven of 
which had renal impairment and achieved SD of fluconazole 
after adjusting for renal dose, and 67 in the LD prophylaxis 
group. Patients in the SD prophylaxis group had a mean age 
of 18.9 years (range: 6 months to 66 years), while patients in 
the LD prophylaxis group were older with a mean age of 34.3 
years (range: 6 months to 68 years), although the difference 
was not statistically significant. Forty-six percent (46%) of the 
patients were male. In about one-third of patients (28.2%), in-
fection with hepatitis C virus was the etiology of end-stage 
liver disease (ESLD). The mean body mass index (BMI) was 
Figure 1. Patient population.
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higher in the LD prophylaxis group versus SD group (26.0 vs. 
19.4, P = 0.01), which might be explained by the greater pa-
tients mean age in the LD prophylaxis group. There were no 
significant differences between the two groups in terms of oth-
er baseline comorbidities. Immunosuppression regimen and 
dose was similar between the two groups. Rejection was more 
frequent in the LD prophylaxis group; however, the difference 
was not statistically significant.
Post-transplant CM status
Post-transplant CM status analyzed between SD and LD 
groups as well as against pre-transplant CM status and du-
ration of prophylaxis are summarized in Figures 2-4. There 
were more patients with positive post-transplant CM status 
in the SD group compared to the LD prophylaxis group (Fig. 
2). When comparing post-transplant status to pre-transplant 
CM status, we found that more patients with positive pre-
transplant status had developed reactivation post-transplant 
(Fig. 3). There was no significant correlation between the 
three groups classified according to duration of prophylaxis 
and post-transplant CM status (Fig. 4). However, their prima-
ry care physicians or private outpatient specialists may have 
placed some patients back on prophylaxis. Other variables in-
cluding demographic information, ESLD etiology, pre-trans-
Table 1.  Sample Baseline Demographics
Baseline characteristics Total number (n = 78) Standard dose (n = 11) Low dose (n = 67) P-value
Age in years (range 6 months to 68 years)
  < 18 years 33 (42.3%) 7 (63.6%) 26 (38.8%) NS
  ≥ 18 years 45 (57.7%) 4 (36.4%) 41 (61.2%)
Mean age 18.9 34.3 NS
Gender
  Male 46 (59.0%) 5 (45.5%) 41 (61.2%) NS
  Female 32 (41.0%) 6 (54.5%) 26 (38.8%)
Race
  White 29 (37.2%) 2 (18.2%) 27 (40.3%) NS
  Non-white 49 (62.8%) 9 (81.8%) 40 (59.7%)
ESLD etiology
  Alcoholic 8 (10.3%) 0 (00.0%) 8 (11.9%) NS
  HCV 22 (28.2%) 2 (18.2%) 20 (29.9%)
  HBV 1 (1.3%) 0 (0.00%) 1 (1.5%)
  NASH 9 (11.5%) 1 (9.1%) 8 (11.9%)
  Other 38 (48.7%) 8 (72.7%) 30 (44.8%)
Weight in pounds, mean* 70.5 136.9 0.01
BMI, mean* 19.4 26.0 0.01
History of DM** 17 (22.1%) 1 (10.0%) 16 (23.9%) NS
History of HTN** 17 (22.4%) 3 (30.0%) 14 (21.2%) NS
History of cancer** 20 (26.3%) 3 (30.0%) 17 (25.8%) NS
Immunosuppression
  Tacrolimus 67 (88.2%) 9 (90.0%) 58 (87.9%) NS
  Prednisone 58 (76.3%) 9 (81.8%) 49 (75.4%) NS
  Mycophenolate mofetil 59 (78.7%) 7 (70.0%) 52 (80.0%) NS
  Sirolimus 6 (8.1%) 1 (10.0%) 5 (7.8%) NS
  Induction therapy 29 (59.2%) 1 (33.3%) 28 (60.9%) NS
Rejection
  Monoclonal Ab beyond 30 days of transplant 4 (9.8%) 0 (0.00%) 4 (11.1%) NS
  Steroid bolus 30 (73.2%) 2 (40.0%) 28 (77.8%) NS
*Weight and BMI calculated before the time of transplant. **Pre-transplant. BMI: body mass index; ESLD: end-stage liver disease; HCV: hepatitis C 
virus; HBV: hepatitis B virus; NASH: non-alcoholic steatohepatitis; DM: diabetes mellitus; HTN: hypertension; Ab: antibody.
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Figure 2. Post-transplant coccidioidomycosis status compared with prophylaxis dose.
Figure 3. Post-transplant coccidioidomycosis status compared with pre-transplant status.
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plant comorbid conditions, immunosuppression and rejection 
were also analyzed in regards to post-transplant CM status, 
but no significant correlations were found. Using multivari-
ate analysis, a statistically significant correlation was found 
between positive pre-transplant status and positive post-trans-
plant status with a hazards ratio of 8.25 (95% confidence in-
terval (CI): 1.028 - 66.192).
Survival analysis
There was a trend towards improved survival in patients who 
had a positive post-transplant CM status in the SD group ver-
sus the LD group (90.9% versus 81.3%) (Fig. 5). However, 
this was not statistically significant. Survival was lower in pa-
tients who were unchecked for post-transplant CM infection, 
suggesting underestimation of detection (Fig. 6). The differ-
ence was not statistically significant.
Individual patient analysis
Given that our study had a small number of patients (N = 78), 
we were able to perform more in-depth analysis of individual 
charts of patients with either positive pre-transplant (eight pa-
tients) and/or positive post-transplant (nine patients) CM status.
Out of the 38 patients who were checked for post-transplant 
CM status, nine (23.7%) were positive. One patient developed 
disseminated infection while on LD prophylaxis 2 years post-
transplant. Two patients developed pulmonary CM: one 4 months 
while on LD prophylaxis and the other 1 year after completion of 
LD prophylaxis. Two patients had asymptomatic serologic con-
version after completion of LD prophylaxis. The first conversion 
was detected 6 months after completion and the second a year af-
ter finishing treatment. There were three patients who were posi-
tive pre-transplant and remained seropositive post-transplant but 
remained asymptomatic (one was in SD group and two were in 
LD group). One patient seroconverted to asymptomatic positive 
post-transplant CM status after completion of 6 months of SD 
prophylaxis. Out of the total 78 included patients, seven patients 
(8.9%) were positive pre-transplant, of which six were placed on 
LD and one was on SD prophylaxis. For those six placed on LD 
prophylaxis, four converted to negative serology post-transplant 
and remained asymptomatic until the end of chart review period. 
The other two patients on LD prophylaxis remained seropositive 
and asymptomatic. The one patient placed on SD prophylaxis 
remained seropositive and asymptomatic.
There was also one patient (excluded from the analysis) 
who underwent transplantation with CM pneumonia. He had 
been placed on SD but died 2 months after transplant from com-
plications of anoxic brain injury caused by hypoxia. Current 
practice protocol based on expert recommendation would make 
Figure 4. Post-transplant coccidioidomycosis status compared with prophylaxis duration.
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any active CM a contraindication to organ transplantation.
Discussion
Coccidioides immitis/posadasii is associated with life-threat-
ening infections among transplant recipients. The risk of infec-
tion among SOT recipients in endemic regions in the absence of 
prophylaxis may reach 9% in the first year after transplantation 
[2]. SOT recipients experience a high rate of disseminated infec-
tion. Therefore, most transplant centers in the endemic regions 
have developed their own prophylaxis protocols. Previously, all 
transplant recipients at the University of Arizona Medical Cent-
er, now Banner University Medical Center, received flucona-
zole at a dose of 50 mg daily for an indefinite period of time for 
prophylaxis. It is unclear as to when or why this particularly low 
dose was chosen at our institution, but the practice was called 
into question when several kidney and heart transplant recipients 
developed breakthrough infections while on 50 mg daily dose.
In our study, there were more patients with a positive 
post-transplant CM status in the SD group compared to the 
LD prophylaxis group. This may point to a possible hidden 
bias where the clinicians at the time may have purposely in-
creased or prescribed the standard dose for these patients. Un-
fortunately, we could not find this information in the charts. 
Additionally, one could speculate that the standard dose had 
been protective in this group. We also found more patients 
with a positive pre-transplant CM status that developed infec-
tion post-transplant. We found a statistically significant corre-
lation between positive pre-transplant CM status and positive 
post-transplant CM status, which highlights the importance of 
pre-transplant status as a predictor of future post-transplant 
infection.
We detected a trend towards improved survival (SD 
group 90.9% versus LD 81.3%) among those with a positive 
post-transplant CM status. However, this survival difference 
was not statistically significant. The lack of significance may 
have been due to low power impact and data that could not 
be located. In addition, the difference found might have been 
due to other infections such as those caused by candida spe-
cies, which respond to fluconazole. Despite the information 
written in the charts we also became aware that many of the 
patients continued higher dose of prophylaxis prescribed by 
community physicians. We found no significant correlation 
between duration of prophylaxis and post-transplant CM sta-
tus; however, it is likely that their primary care physicians or 
private outpatient specialists may have placed some patients 
back on prophylaxis, as this is a common practice in Arizona 
after patients return to the community. Another important fac-
tor to highlight is the decreased sensitivity of serologic testing 
in SOT. Serological antibody testing for CM is useful but may 
provide false negative results in immunosuppressed patients. 
Figure 5. Survival based on antifungal prophylaxis dose.
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Blair and colleagues reported the positivity for any single se-
rologic test ranging from 21% to 56% in these populations, 
which may have impacted the results of our study [5].
Distinction between asymptomatic and active infection 
was challenging based on chart reviews and certain patients 
had received their care at other institutions, including the group 
that had their testing results reported to the health department. 
Survival was lower in patients who were unchecked for post-
transplant CM suggesting underestimation of detection but the 
difference was not statistically significant. Despite the lack of 
statistical significance in the current study, we have changed our 
protocol and currently use universal prophylaxis for 12 months 
with SD of fluconazole (200 mg daily with renal dose adjust-
ment) post-transplant with the exception of liver transplant re-
cipients who receive universal prophylaxis for only 6 months 
to avoid risk of associated hepatotoxicity. Since the institution 
of SD prophylaxis at our institution, we have not diagnosed 
further new post-transplant infections. We also utilize the pro-
posed prophylaxis by Blair et al where patients with a history 
of recent CM or positive serologic results during the period of 
transplantation receive fluconazole at 200 mg/day for life [6].
We understand that our study may not have had the num-
ber of subjects needed to show significance between SD and 
LD prophylaxis. A large prospective randomized clinical trial 
would best answer the questions raised in this study. Finally, 
patients undergoing liver transplantation tend to receive lower 
doses of immunosuppression; therefore, a larger study that in-
cludes renal, lung and heart transplant recipients may provide 
even better results.
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